Background: Clinical success of poly(ADP-ribose) polymerase inhibitors (PARPi) has been limited to repair-deficient cancers and by resistance. Oncolytic herpes simplex viruses (oHSVs) selectively kill cancer cells, irrespective of mutation, and manipulate DNA damage responses (DDR). Here, we explore potential synthetic lethal-like interactions between oHSV and PARPi. Methods: The efficacy of combining PARPi, oHSV MG18L, and G47D in killing patient-derived glioblastoma stem cells (GSCs) was assessed using cell viability assays and Chou-Talalay synergy analysis. Effects on DDR pathways, apoptosis, and cell cycle after manipulation with pharmacological inhibitors and lentivirus-mediated knockdown or overexpression were examined by immunoblotting and FACS. In vivo efficacy was evaluated in two GSC-derived orthotopic xenograft models (n ¼ 7-8 per group). All statistical tests were two-sided. Results: GSCs are differentially sensitive to PARPi despite uniform inhibition of PARP activity. oHSV sensitized GSCs to PARPi, irrespective of their PARPi sensitivity through selective proteasomal degradation of key DDR proteins; Rad51, mediating the combination effects; and Chk1. Rad51 degradation required HSV DNA replication. This synthetic lethal-like interaction increased DNA damage, apoptosis, and cell death in vitro and in vivo. Combined treatment of mice bearing PARPi-sensitive orresistant GSC-derived brain tumors greatly extended median survival compared to either agent alone (vs olaparib: P.001; PARPi, oHSV, and combination, respectively). Conclusions: The unique oHSV property to target multiple components of DDR generates cancer selective sensitivity to PARPi. This combination of oHSV with PARPi is a new anticancer strategy that overcomes the clinical barriers of PARPi resistance and DNA repair proficiency and is applicable not only to glioblastoma, an invariably lethal tumor, but also to other tumor types.
are repaired by error-free HR, or error-prone nonhomologous end joining (NHEJ) and PARP-dependent alternate NHEJ (Alt-NHEJ) (3) . If HR is deficient, DSBs are repaired by NHEJ and Alt-NHEJ, which result in genomic instability. This is the basis for synthetic lethality of PARP inhibitors (PARPis) in HR-defective tumors and their development as cancer therapeutics (2, 4) . However, challenges for PARPi therapy remain: improving their efficacy in HR-deficient tumors, overcoming drug resistance, and expanding their use to tumors without characterized defects in HR.
Viruses, including herpes simplex virus (HSV), are actively involved in manipulating DDR (5) , providing a rationale for combination with PARPi. Oncolytic HSV (oHSV), a new class of anticancer agent, is genetically engineered to selectively replicate in and kill cancer cells, amplifying and spreading within the tumor but not normal tissue (6) . oHSVs have been safely administered to glioblastoma (GBM) patients (7), and oHSV talimogene laherparepvec was recently approved by the US Food and Drug Administration (FDA) for recurrent melanoma (8) . GBM, a primary malignant brain tumor, has a median survival of about 15 months, which has not markedly improved (9) . GBM stem cells (GSCs) are a subpopulation of highly tumorigenic cells with stem cell-like properties (10, 11) . GSCs maintain the genotypes/ phenotypes of the patient's tumors from which they were isolated, including heterogeneous histopathology (12, 13) . They are important in disease progression, recurrence, and resistance to therapy, and thus they are a critical therapeutic target (10, 14, 15) .
In this study, we investigated the therapeutic interaction between oHSV and PARPis in killing patient-derived PARPi-sensitive and -resistant GSCs and inhibiting tumor growth and how the manipulation of DDR pathways contributes to combinatorial efficacy.
Methods

Cells and Viruses
Human GSCs were isolated as previously described and cultured in EF20 medium with EGF and FGF2 (16) . OHSV G47D (c34.5D, ICP47-Us11 promoterD, ICP6-, LacZþ) (17) , and MG18L (Us3D, ICP6-, LacZþ) (18) were grown and titered on Vero cells.
Cell Assays
Cell viability was measured by MTS assay after dissociated cells plated in triplicate in 96-well plates were treated at 37 C for six days. Chou-Talalay analysis was performed as described (19) . For cell cycle analysis, fixed cells were stained with propidium iodide and analyzed with flow cytometry.
Immunoblotting
Cells were lysed in radioimmunoprecipitation (RIPA) buffer (Boston BioProducts) with protease and phosphatase inhibitors (Roche Diagnostics, Indianapolis, IN). After electrophoresis, proteins were transferred to PVDF membranes and incubated with primary and secondary antibodies.
In Vivo Experiments
Female athymic mice (age 7-8 weeks; National Cancer Institute, Frederick, MD) were intracerebrally implanted with GSCs as in (16) and randomly assigned to four groups. Olaparib (50 mg/kg) or vehicle was administrated intraperitoneally, and MG18L or PBS was injected intratumorally. Mice were monitored for clinical symptoms, and moribund mice were killed and the presence of tumor confirmed. All in vivo procedures were approved by the Subcommittee on Research Animal Care at Massachusetts General Hospital.
Statistical Analysis
In vitro studies (relative cell viability) were analyzed using generalized linear models, and least square means after adjustment per group are presented for the group estimates. P values were adjusted for multiple comparisons within the models using Tukey adjustment. Unpaired t test was used as indicated for two-group comparisons. Survival was analyzed by KaplanMeier plot, and log-rank (Mantel-Cox) test was used to compare between survival curves. Prism (GraphPad), MedCalc, and SAS software were used for analysis. P values of less than .05 were considered statistically significant. All statistical tests were two-sided. Detailed information on these and all other methods can be found in the Supplementary Materials (available online).
Results
Sensitivity of GSCs to PARPi
Patient-derived GSCs exhibited differential sensitivity to olaparib (Lynparza, AZD2281), an approved, potent PARP1/2 inhibitor currently in clinical trial for GBM (2) . Four GSCs (MGG4, MGG6, MGG8, and MGG23) were sensitive (IC50 < 20 lM), close, or below the maximal plasma concentration (6 lg/mL or 14 lM) in patients receiving the standard 400 mg dose (20) , and four (MGG13, MGG18, MGG24, and BT74) were resistant (IC50 > 100 lM) ( Figure 1A ; Supplementary Table 1, available online). A similar trend in sensitivity was seen with additional PARP1/2 inhibitors veliparib, rucaparib, and BMN673, which are in clinical trial, with MGG23 somewhat intermediate in sensitivity (Figure 1A;  Supplementary Table 1, available online) . Importantly, normal human astrocytes were relatively resistant to all four PARPis ( Figure 1B ; Supplementary Table 1, available online). GSC resistance was not due to PARPi inactivation as olaparib similarly inhibited PARP in GSCs, as measured by PARP enzymatic activity ( Figure 1C ) and PARylation ( Figure 1D ). For subsequent experiments, we used olaparib as a representative PARPi.
Interaction of oHSV with PARPi in Killing Sensitive and Resistant GSCs in Vitro
We hypothesized that oHSV would enhance PARPi efficacy. GSCs vary in their sensitivity to killing by oHSV, either MG18L, deficient in blocking virus-induced apoptosis, or G47D, currently in clinical trial for recurrent glioma (7, (17) (18) (19) , but none were resistant and there was no association with PARPi sensitivity (Figure 2A ; Supplementary Table 1, available online). We then tested whether oHSV altered PARPi sensitivity. A fixed dose of MG18L with a range of olaparib doses, or a fixed dose of olaparib with a range of MG18L doses in PARPi-sensitive (MGG4 and MGG23) and -resistant GSCs (BT74 and MGG24), shifted the combination dose response curves to lower doses in all cases compared with those for the single treatment (Figure 2 , B-E, left and middle; Supplementary Figure 1A , available online). In the PARPi-sensitive GSCs, the combination of MG18L or G47D with olaparib was synergistic, as determined by Chou-Talalay analysis ( Figure 2 GSCs were plated at 5000 cells/well, except MGG24 and BT74 at 8000 cells/well, and treated the next day with indicated PARPis (olaparib, veliparib, rucaparib, and BMN673) at different doses for six days, followed by MTS assay for cell viability. Nonlinear regression curves (log(inhibitor) vs response) were plotted. B) Dose response curves for PARPis on normal human astrocytes. Cells were plated at 3000 cells/well and treated as in (A). C) PARP activity, as measured by PARP Assay Kit, was inhibited in all GSCs after olaparib treatment (Ola (þ), 30 lM) for 24 hours. Data are represented as mean 6 SD. D) PARylated proteins (PAR), a measure of PARP activity, were detected by immunoblotting after treatment with indicated doses of olaparib for 24 hours in MGG4 and BT74. b-actin is loading control. Ola ¼ olaparib; PARP ¼ poly(ADPribose) polymerase. 
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Effect of oHSV and PARPi on DDR and Apoptosis
The effect of treatment on DDR pathways was examined. oHSV did not alter olaparib's inhibition of parylation (PAR) ( Figure 3A ; Supplementary Figure 2C , available online). We previously showed that G47D induces DSBs in infected GSCs (19) . Both G47D and MG18L induced DSBs, as detected with cH2AX, in PARPi-sensitive and -resistant GSCs ( Figure 3A ; Supplementary Figure 2C , available online). DSBs accumulated at late times (Supplementary Figure  2D , available online), suggesting impaired DNA repair. Apoptosis, as assessed by cleaved-caspase 3 and cleaved-PARP, was induced similarly to cH2AX, with MG18L inducing more apoptosis than G47D ( Figure 3A ; Supplementary Figure 2C , available online). Both DNA damage and apoptosis were greatly and further increased after combination treatment in all GSCs (O þ M, O þ G) ( Figure 3A ; Supplementary Figure 2C , available online).
ATM and ATR, DNA damage protein kinases activated by DSBs and SSBs, respectively, initiate HR repair and cell cycle checkpoints (21) . ATM was activated (p-ATM) by olaparib or virus alone, but not increased with combination ( Figure 3A ). Activated ATR phosphorylates Chk1, a key component in DNA damage-induced cell cycle arrest and HR repair (22) . P-Chk1 was strongly induced by olaparib alone in all GSCs except MGG24, and by the combination with oHSV only in MGG4 ( Figure 3A Loss of Rad51 would disable HR, so we examined whether oHSV inhibits HR in tumor cells using a I-SceI-induced DSB/HR reporter assay (23) . For these studies, we used DR-GFP stably transduced U20S cells. oHSV induces Rad51 loss in U20S cells (Supplementary Figure 4B , available online). HR repair of the introduced DSBs generates functional GFP compared with non-ISceI-transfected cells ( Figure 3 , B and C; mock vs nontransfected). MG18L infection of most of the cells ( Figure 3B , X-gal), 24 hours after transfection, statistically significantly reduced HR repair by over 50% (Figure 3 , B-D, GFPþ).
Effect of oHSV and PARPi on Cell Cycle of PARPiSensitive and -Resistant GSCs P-Chk1 phosphorylates multiple effectors for cell cycle arrest (22), so we examined treatment effects on cell cycle. Olaparib alone induced a decrease in G1 cells and some cell cycle arrest in S and G2/M phases in MGG4, while in BT74 there was a large S phase arrest and decrease in G2/M ( Figure 3E ; Supplementary Figure 3A , available online), which may enable time for DNA repair. MG18L did not statistically significantly alter S or G2/M phase cells ( Figure 3E ). However, olaparib-induced S phase arrest was further increased by MG18L in MGG4 and decreased in BT74 ( Figure 3E ), likely a reflection of the induction or loss of pChk1 ( Figure 3A) . In both GSCs, the combination greatly increased the sub-G1 population, indicative of dying and apoptotic cells ( Figure 3E ). CHIR-124, a potent and selective Chk1 kinase inhibitor (24) , only abrogated cell cycle arrest when the treatment activated Chk1 (Supplementary Figure 3B , available online).
Proteasomal Degradation of Rad51 and Chk1 and oHSV Life Cycle
To determine the mechanism of protein loss, we used MG132, a reversible proteasome inhibitor (25) . MG132 completely blocked MG18L-induced degradation of Rad51 and Chk1 ( Figure 4A ) and eliminated synergy between olaparib and MG18L in MGG4 ( Figure 4B ) and sensitization in BT74 ( Figure 4C ) at a relatively nontoxic dose that did not affect MG18L cytotoxicity (Supplementary Figure 4A , available online). HSV ICP0 is an immediate-early gene encoding a RING finger E3 ubiquitin ligase that mediates the degradation of host proteins, including DDR (26) . However, ICP0 mutant viruses HSV 7134 (27) and KOS RFm (28), with delayed replication kinetics (HSV ICP4 and late gC expression), induced degradation of Rad51 and Chk1 after infection of BT74 ( Figure 4D ) and U20S cells (Supplementary Figure 4B , available online) like the rescued wild-type viruses (7134R and KOS RFr), demonstrating that ICP0 is not necessary for degradation. Rad51 RNA is not selectively degraded after MG18L infection (Supplementary Figure 5A , available online).
As Rad51 and Chk1 degradation occurred coincident with gC expression ( Figure 4D ), which is dependent upon virus DNA replication (29), we tested whether HSV DNA replication was required. Acyclovir, a nucleoside analog inhibitor of HSV DNA replication (30) , blocked virus replication (Supplementary Figure 5C , available online) and MG18L-induced degradation of Rad51 and Chk1 in GSCs ( Figure 4E ). It abrogated MG18L cytotoxicity, as expected, but also the combination effect with PARPi in both MGG4 and BT74 cells ( Figure 4F ). oHSV G207 infection of GSCs is nonpermissive (16) , with a block in true late (c2) protein synthesis (CP and SDR) (unpublished results), but no effect on virus DNA replication (Supplementary Figure 5B , available online). In contrast to acyclovir, where late proteins are also not expressed, both Rad51 and Chk1 were degraded after G207 infection, similar to MG18L ( Figure  4E ). This supports the necessity of HSV DNA replication for proteasomal degradation of Rad51 and/or Chk1.
Role of Rad51 Loss in Synergy Between oHSV and PARPi
We tested whether Rad51 loss alone was necessary for synergy. Rad51 silencing, using lentivirus-mediated shRNA ( Figure 5A ), Figure 2 . Continued and C) Interaction between olaparib (Ola) and MG18L or G47D in MGG4 and MGG23, as determined by the Chou-Talalay median effect method (19, 40) . Combination index < 1, ¼ 1, and > 1 indicates synergistic, additive, and antagonistic interactions, respectively. Right: D and E) Combination of olaparib and G47D in BT74 (Ola ¼ 10 lM) and MGG24 (Ola ¼ 5 lM). Increasing virus dose is statistically significantly different from the previous dose, with or without olaparib (P < .0001). *P ¼ .004; †P < .001; ‡P < .0001 (multiple comparisons test, Tukey). F) Combination of olaparib (10 lM, Ola (þ)) and MG18L or G47D (0.1 MOI) in astrocytes. Cell viability was determined by MTS assay after six-day treatment and represented as mean 6 SD. All statistical tests were two-sided. MOI ¼ multiplicity of infection; Ola ¼ olaparib; PARP ¼ poly(ADP-ribose) polymerase. Figure 6A , available online) and sensitized both MGG4 and BT74 to olaparib or oHSV alone, but abrogated the combination effect, so that cytoxicity was similar to oHSV monotherapy ( Figure 5 , B and C). This was confirmed by viable cell counting (Supplementary Figure  6B , available online). The combination was now antagonistic in the Rad51-silenced MGG4 cells, while still synergistic in control shRNA-transduced cells ( Figure 5D ). Thus, increased sensitivity to PARPi due to Rad51 silencing compensates for the effect of oHSVinduced Rad51 loss, indicating that this mediates oHSV synergy and synthetic lethality with PARPi.
Role of Chk1 in the Combination Effect of oHSV and PARPi
Chk1 was activated in MGG4 by olaparib and in combination ( Figure 3A) . While CHIR-124 sensitized MGG4 to olaparib, suggesting p-Chk1 was protective, it did not alter the combination with oHSV ( Figure 6A ), discounting Chk1 signaling in mediating this combination effect. CHIR-124 did not sensitize BT74 to olaparib (Supplementary Figure  6C , available online). Overexpression of Chk1 in BT74, where it was degraded by oHSV, resulted in some Chk1 remaining and being activated after MG18L infection ( Figure 6B ; Supplementary Figure 6D , available online). This did not alter the sensitivity of MGG23 or BT74 to olaparib or oHSV alone, but partially rescued GSCs from combination cytotoxicity ( Figure 6C ), suggesting that oHSV-induced Chk1 degradation contributes to this.
We combined Chk1 inhibition with Rad51 silencing to test whether this phenocopied the effect of oHSV. The absence of Rad51 did not alter CHIR-124 sensitivity, but CHIR-124 did increase olaparib sensitivity in Rad51-silenced MGG23 and BT74 ( Figure 6D ). This was associated with increased apoptosis (cleaved-PARP) and DSBs (cH2AX) in Rad51-silenced GSCs treated with olaparib and additionally when combined with CHIR-124 ( Figure 6E ), phenocopying the effect of oHSV.
Efficacy of Combination Therapy on Survival of Mice Bearing PARPi-Sensitive and -Resistant GSC-Derived Intracerebral Tumors
We then tested the combination therapy in vivo in PARPi-sensitive and -resistant GSC-derived brain tumors. In orthotopic MGG4 xenografts, olaparib alone statistically significantly prolonged survival (median survival ¼ 94 days, 95% confidence interval [CI] ¼ 75 to 107), compared with mock (median survival ¼ 83 days, 95% CI ¼ 77 to 86, P ¼ .03), similar to the prolongation seen with a single intratumoral injection of MG18L (median survival ¼ 102 days, 95% CI ¼ 85 to 110, P ¼ .003) compared with mock. The combination of olaparib and MG18L further extended survival (median survival ¼ 131 days, 95% CI ¼ 108 to 170; olaparib þ MG18 vs MG18, P ¼ .005, and vs olaparib, P ¼ .001) by over 50% compared with mock ( Figure  7A ). In the BT74 model, MG18L alone, as in MGG4, statistically significantly prolonged survival (median survival for MG18L ¼ 62 days, 95% CI ¼ 56 to 72; mock ¼ 54 days, 95% CI ¼ 52 to 58, P ¼ .009), whereas olaparib alone had no effect (median survival ¼ 56 days, 95% CI ¼ 52 to 61) ( Figure 7B ). However, the combination of olaparib and MG18L further extended survival (median survival ¼ 75 days, 95% CI ¼ 64 to 90; olaparib þ MG18 vs MG18, P ¼ .005, and vs olaparib, P ¼ .0004) ( Figure 7B ), suggesting a synthetic lethal-like effect in vivo.
DNA Damage and Apoptosis After Combination Therapy in Vivo
To gain mechanistic insight, we examined DDR in tumor lysates. PARP inhibition demonstrated olaparib blood-brain barrier transit and tumor penetration (PAR) ( Figure 7C ). MG18L infected all injected tumors to a similar extent, as detected by HSV early protein ICP8 expression (HSV-ICP8) ( Figure 7C ). DNA damage was induced by MG18L alone and greatly increased when combined with olaparib (cH2AX) ( Figure 7C ). Strikingly, apoptosis was only induced after combination treatment in both MGG4 and BT74 (cleaved-PARP) ( Figure 7C ). This is consistent with the in vitro results, showing that increased DNA damage and apoptosis likely contributed to the combination effect in vivo. Rad51 and Chk1 were clearly reduced in BT74 with MG18L alone or in combination ( Figure 7C, right) . In MGG4, four out of six tumors exhibited a decrease in Rad51 after MG18L treatment ( Figure 7C , left), with Rad51 statistically significantly lower in MG18L treated (mean ¼ 0.51 6 0.07) than mock alone (mean ¼ 0.71 6 0.06, P ¼ .04) or mock combined with olaparib (mean ¼ 0.87 6 0.10, P ¼ .01) (Supplementary Figure 7 , available online). P-Chk1 was only detected after combination treatment in MGG4 (Figure 7C, left) .
Discussion
Here we report that oHSV sensitizes GSCs to PARPi killing in a synthetic lethal-like fashion in vitro and in vivo through targeting DDR. PARPi sensitivity in cancer cells is usually due to genetic alterations in DDR genes, particularly HR repair, as demonstrated with BRCA1 and BRCA2 mutated breast and ovarian cancer (2) . In cancer cells without identified DNA repair deficiencies, pharmacological inhibition of DDR can induce synthetic lethality with PARPi (4). We hypothesized that oHSV would induce synthetic lethality with PARPi as it induces DNA damage and modulates DDR (19) . In contrast to our previous studies with temozolomide (19) , here we identify a new activity of oHSV, proteasomal degradation of Rad51, mediating synergy with PARPi. Two oHSVs with different mutations and cancer selectivity mechanisms, G47D and MG18L (6), similarly synergized with olaparib in PARPi-sensitive and -resistant GSCs. In contrast to oncolytic adenovirus (31), we did not find any effect of olaparib on oHSV replication.
Activation of Chk1 by ATR mediates cell cycle arrest to allow time for DNA repair and prevent cells with damaged DNA from entering mitosis (22) . P-Chk1 was induced by olaparib alone in all GSCs, except MGG24, and resulted in S phase arrest. Virus infection led to loss of Chk1 protein, completely in PARPi-resistant 
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BT74 and MGG24 and to a lesser extent in PARPi-sensitive GSCs. This was unexpected as HSV-1 was previously shown not to affect the stability of ATR pathway proteins, including Chk1 (5). Chk1 inhibition reportedly synergized with olaparib in prostate cancer cells (32) , similar to MGG4. Chk1 inhibitor blocked olaparib-induced S phase arrest when Chk1 was activated but did not sensitize MGG23 or BT74 cells to olaparib. Conversely, overexpression of Chk1 counteracted oHSV-induced degradation and partially abrogated oHSV and olaparib combination cytotoxicity, coincident with Chk1 activation. HR is a major repair pathway for DSBs, using an intact sister chromatid as a template for Rad51-catalyzed DNA strand exchange to guide error-free repair (3). Unexpectedly, oHSV infection induced a loss of Rad51 within 30 hours in all GSCs tested and inhibited HR. The most obvious viral proteins, ICP0 and Us3, were not involved. oHSV-induced Rad51 loss was abrogated by MG132 or acyclovir but not G207, which replicates its DNA but doesn't express c2 proteins, demonstrating that this was due to proteasome-dependent degradation and required viral DNA replication. We postulate that something in the physical structure of HSV-replicating DNA and/or its location in the nucleus alters Rad51 so it is degraded. Rad51 shRNA-transduced GSCs were more sensitive to olaparib than control shRNA-transduced GSCs, in line with previous studies of cancer cell lines (33, 34) . Rad51 silencing also increased the cytotoxicity of oHSV in GSCs; however, the combination of oHSV and olaparib was now antagonistic. Thus, synergy between olaparib and oHSV is mediated by viral inhibition of Rad51. This would suggest that the synergistic effects with oHSV would not occur in cells with HR repair deficiencies that are already synthetic-lethal with PARPi. In vivo, olaparib alone statistically significantly extended the survival of athymic mice bearing only PARPi-sensitive GSCderived tumors. In contrast, MG18L alone improved overall survival in both tumor models, illustrating the broad efficacy of oHSV. Most importantly, the combination of olaparib with MG18L greatly increased survival in both PARPi-sensitive and -resistant GSC-derived tumors, indicating a synergistic effect in vivo. This is in contrast to TMZ and PARPi, where there was no combination effect in MGMT unmethylated xenografts (35) . In both GSCs, combination therapy induced the greatest DNA damage and apoptosis. P-Chk1 was detected only in MGG4 after combination treatment, which might be a nonconsequential response to DNA damage or contribute to efficacy in vivo and not in vitro.
Our study is not without limitations. The large diversity between different patient GSCs, genomically and phenotypically (13, 36, 37) , means we have likely missed the full range of complexity despite examining eight different GSCs. While we demonstrated a novel potential mechanism regulating Rad51 degradation, we have not defined how viral DNA replication might promote degradation. The treatment schedule in vivo was not optimized, such as with multiple administrations of oHSV that improve efficacy, nor was pharmacologic synergy in vivo demonstrated. The in vivo studies were performed in immunodeficient mice. It is possible that the combination effect would be altered in immunocompetent mouse models because of oHSV and/or PARPi effects on immune cells (38, 39) .
These studies describe a novel synthetic lethal-like combination therapy for targeting GSCs with PARPi and oHSV. We propose a model (Figure 8 ) in which PARPi treatment of GSCs blocks BER and activates DDR, including S phase arrest through Chk1 activation, while oHSV induces DSBs, inhibits HR repair through degradation of Rad51 because of DNA replication, and alters the cell cycle through Chk1 degradation, with the combination driving repair toward lethal NHEJ or other cell death pathways. Therefore, this combination strategy could be effective for GBM irrespective of molecular subtypes and DDR pathways that may be deficient in individual patients. This unique ability of oHSV to disrupt multiple interconnected components of DDR makes it a powerful therapeutic to combine with other DNA-damaging agents or inhibitors of DDR. Because of oHSV's broad efficacy against most solid tumors, this novel combination strategy should be applicable to other cancer stem cells and tumors.
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